15 June 2021
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Chief Financial Officer and Director, Paul Stockdale, has purchased 8,000 Ordinary Shares of 1 pence each ("shares") at an average price of 56.24p per share.
Following this transaction, Paul Stockdale is interested in 23,000 Ordinary Shares, representing 0.02% of the Company's current issued share capital.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name | Paul Stockdale | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Director/PDMR | ||||
| b) | Initial notification/ Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Oxford BioDynamics Plc | ||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 | ||||
| b) | Nature of the transaction | Acquisition of ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price
|
| ||||
| e) | Dates of the transactions | 15 June 2021 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
For more information:
| Oxford BioDynamics Plc | Tel: +44 (0)1865 518910 |
| Jon Burrows, CEO Paul Stockdale, CFO |
|
|
|
|
| Shore Capital - Nominated Adviser and Broker | Tel: +44 (0)20 7408 4090 |
| Advisory: Edward Mansfield / John More Broking: Fiona Conroy |
|
|
|
|
| Instinctif Partners - Financial PR | Tel: +44 (0)20 7457 2020 |
| Melanie Toyne-Sewell / Agnes Stephens / Katie Duffell / Nathan Billis | OxfordBioDynamics@instinctif.com |
|
|
|
| PCG Advisory Group - US Investor Relations | Tel: +1 646 863 6341 |
| Jeff Ramson / Kirin Smith |
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit. Its next product will be a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, to be launched later in 2021.
The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial team in the US and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow on Twitter or LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
Oxford BioDynamics is leveraging its leading technology to develop a pipeline of tests in a wide range of indications, such as immuno-oncology, oncology, and veterinary medicine, to follow the release of its EpiSwitch® CST (Covid Severity Test).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
